A. Petersmann received consulting and contract fees from Tosoh Bioscience, Radiometer, Roche Diagnostics, Nova Biomedical, Siemens Healthineers, Becton Dickinson.; D. Müller-Wieland declares potential conflicts of interest: Member of Advisory Boards and has received lecture fees: Amarin, Amgen, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, MSD, AstraZeneca, Novo Nordisk, Novartis, Sanofi.; U.A. Müller has not received any personal fees or travel expenses from pharmaceutical companies. Public declaration of interests: https://www.akdae.de/Kommission/Organisation/Mitglieder/DoI/Mueller.pdf ; R. Landgraf declares the following potential conflicts of interest: Advisory Boards: Lilly Deutschland, Novo Nordisk Pharma; presentation fees: AstraZeneca, Berlin Chemie, Lilly Deutschland, Novo Nordisk Pharma. Other activities: Authorized representative of the Executive Board of the German Diabetes Foundation, Steering Committee for the Development and Updating of the National Care Guidelines for Diabetes. M. Nauck received consulting and contract fees from Tosoh Bioscience, Radiometer, Roche Diagnostics, Nova Biomedical, Siemens Healthineers, Becton Dickinson.; G. Freckmann is medical director and managing director of the IfDT (Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH at the University of Ulm, Ulm), which carries out clinical studies on medical products for diabetes therapy on its own initiative or on behalf of various companies. GF/IDT has received lecture/consultancy fees from Abbott, Ascensia, Dexcom, LifeScan, Menarini Diagnostics, Metronom Health, Novo Nordisk, Roche, Sanofi, Sensile and Ypsomed.; L. Heinemann is a shareholder of Profil Institut für Stoffwechselforschung GmbH, Neuss. He is a consultant to a number of companies developing new diagnostic and therapeutic options for diabetes therapy.; E. Schleicher declares no conflict of interest.